Chikungunya Treatment: A Comprehensive Review

Chikungunya Treatment: A Comprehensive Review

Author Name : Gurleen Kaur, Manvi Rana, Sapna Rani

ABSTRACT : Following the discovery of the chikungunya virus (CHIKV), isolated cases and outbreaks have been documented in several African nations, the Indian subcontinent, and south-east Asia. The number of reports of CHIKV infections from African nations has increased over the past 20 years, but due to underdiagnosis and underreporting, the overall picture of the virus's spread across the continent is still poorly understood. Furthermore, little is known about how the virus affects public health in Africa, particularly when there is an outbreak. Severe or atypical types of CHIKF have been linked to advanced age and several comorbidities. As of right now, there are no chikungunya virus (CHIKV) vaccines that have been authorized, and patient symptoms are treated with medication. Emerging as a severe public health concern is the arbovirus infection known as chikungunya fever. The Chikungunya virus is its etiological agent (CHIKV). Aedes mosquitoes are the primary vectors of this virus's spread, while reports of vertical and blood transfusion transmission have also been made. The primary reason of the disease's significant morbidity is the arthralgia and arthritis that are produced. The Aedes mosquito's habitat has grown because of the effects of climate change as well as greater globalization of travel and business. Consequently, in the upcoming years, a growing number of individuals will be susceptible to chikungunya fever. While vaccines and targeted antiviral therapies are still being developed, monitoring and vector control are crucial to preventing epidemics and re-emergence.